Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > NY-ESO-1 > CHEK-STP114

NY-ESO-1 specific TCR-HEK293 cell line

ACROBiosystems can provide the customized peptide-MHC I complex service to accelerate your relevant research. Click here to learn more

Order Now

  • Description
    NY-ESO-1 specific TCR-HEK293 cell line
  • Application

    Binding assay by FACS and cell based ELISA.

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (5 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    NY-ESO-1 specific TCR-HEK293 cell line
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 NY-ESO-1 FACS

FACS analysis NY-ESO-1 specific TCR on NY-ESO-1 specific TCR-HEK293 cell line.
FACS assay shows that PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein can bind to NY-ESO-1 specific TCR-HEK293 cell line. NY-ESO-1 specific TCR-HEK293 cell line was red line, Negative control HEK293 cells was grey line (QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. This cell can specifically recognize HLA-A2/NY-ESO-1.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : Inquire

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:16 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message